EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Mediation Analysis of Urine Osmolality and Response to Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Assessment

Ryo Matsuura iD, Kent Doi, Zhen Zhang, Katherine Maringer, Sachin Hajarnis iD, Yoshifumi Hamasaki iD

Nephrology · 2026

DOI: 10.1111/nep.70292 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nephrology, 2026. Verfasst von Ryo Matsuura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Endocrinology, Graduate School of Internal Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Tolvaptan, Polycystic Kidney, Autosomal Dominant, Antidiuretic Hormone Receptor Antagonists, Kidney. Die Arbeit nennt 20 Literaturangaben. Gefördert von: Otsuka Pharmaceutical Development and Commercialization, Inc., Otsuka Pharmaceutical Development and Commercialization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Tolvaptan delays growth in total kidney volume (TKV) and decline in estimated glomerular filtration rate (eGFR) among individuals with autosomal dominant polycystic kidney disease (ADPKD) at elevated risk of rapid progression. We evaluated changes in urine osmolality (Uosm) after treatment initiation as a potential biomarker of long‐term response.

Methods

This was a post hoc analysis of TEMPO 3:4, a 3‐year, randomized, placebo‐controlled trial of tolvaptan. Causal mediation analysis assessed if the effect of tolvaptan on longer‐term outcomes of change in eGFR and TKV at month 36 was mediated by change in Uosm at week 3. Analyses were performed separately for non‐Japanese and Japanese participants.

Results

The average causal mediation effect (ACME) of change in Uosm on eGFR at month 36 was statistically significant (2.4; 95% quasi‐Bayesian confidence interval [CI] 1.2, 3.6) in the non‐Japanese cohort ( n = 948). In the Japanese cohort ( n = 138), whereas the ACME for change in Uosm was non‐significant (−0.3 [95% CI: −2.3, 1.7]), the average direct effect (ADE) of tolvaptan on eGFR was statistically significant (8.4 [95% CI 3.1, 12.4]). For percentage change in TKV, the ADE of tolvaptan was statistically significant in both the non‐Japanese (−8.3 [95% CI: −10.5, −6.3]) and Japanese cohorts (−12.0 [95% CI: −17.4, −7.5]).

Conclusion

This study supported short‐term change in Uosm as a predictive biomarker of longer‐term kidney function in a non‐Japanese cohort; the relationship was not significant in the smaller Japanese cohort. Tolvaptan exhibited a direct treatment effect on the growth of kidney volume in both cohorts of ADPKD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TolvaptanPolycystic Kidney, Autosomal DominantAntidiuretic Hormone Receptor AntagonistsKidneyHumansOsmolar ConcentrationFemaleGlomerular Filtration RateMaleAdultMiddle AgedTreatment OutcomeJapanBiomarkersTime Factors

Stichwörter der Autor:innen

autosomal dominantbiomarkersmediation analysisosmolar concentrationpolycystic kidneytolvaptan

Substanzen

TolvaptanAntidiuretic Hormone Receptor AntagonistsBiomarkers

Autor:innen und Institutionen

  • Department of Nephrology and Endocrinology, Graduate School of Internal Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Emergency and Critical Care Medicine, The University of Tokyo Hospital, Tokyo, Japan.
  • Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, New Jersey, USA.
  • Department of Haemodialysis and Apheresis, The University of Tokyo Hospital, Tokyo, Japan.

ORCID-Profile: Ryo Matsuura, Sachin Hajarnis, Yoshifumi Hamasaki

Förderung

  • Otsuka Pharmaceutical Development and Commercialization, Inc.
  • Otsuka Pharmaceutical Development and Commercialization

Zitieren

APA

Matsuura, R., Doi, K., Zhang, Z., Maringer, K., Hajarnis, S., & Hamasaki, Y. (2026). Mediation Analysis of Urine Osmolality and Response to Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Assessment. Nephrology. https://doi.org/10.1111/nep.70292

Vancouver

Matsuura R, Doi K, Zhang Z, Maringer K, Hajarnis S, Hamasaki Y. Mediation Analysis of Urine Osmolality and Response to Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Assessment. Nephrology. 2026. doi:10.1111/nep.70292

BibTeX
@article{Matsuura2026,
  author = {Matsuura, Ryo and Doi, Kent and Zhang, Zhen and Maringer, Katherine and Hajarnis, Sachin and Hamasaki, Yoshifumi},
  title = {Mediation Analysis of Urine Osmolality and Response to Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Assessment},
  journal = {Nephrology},
  year = {2026},
  doi = {10.1111/nep.70292}
}
Kostenlos starten →